董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Victor Sandor | 男 | Director | 53 | 未披露 | 未持股 | 2020-08-21 |
| Paul A. Friedman | 男 | Chairman of the Board, Director | 77 | 未披露 | 未持股 | 2020-08-21 |
| Kelvin Neu | 男 | Director | 46 | 未披露 | 未持股 | 2020-08-21 |
| Kris Vaddi | -- | Chief Executive Officer and Director | 55 | 207.94万美元 | 未持股 | 2020-08-21 |
| David Bonita | 男 | Director | 45 | 未披露 | 未持股 | 2020-08-21 |
| Mardi C. Dier | 女 | Director | 56 | 未披露 | 未持股 | 2020-08-21 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Brian Piper | 男 | Chief Financial Officer | 48 | 未披露 | 未持股 | 2020-08-21 |
| Kris Vaddi | -- | Chief Executive Officer and Director | 55 | 207.94万美元 | 未持股 | 2020-08-21 |
| David Mauro | 男 | Chief Medical Officer | 55 | 78.42万美元 | 未持股 | 2020-08-21 |
| Peggy A. Scherle | 女 | Chief Scientific Officer | 59 | 未披露 | 未持股 | 2020-08-21 |
| Andrew P. Combs | 男 | Executive Vice President and Head of Chemistry | 54 | 77.28万美元 | 未持股 | 2020-08-21 |
| Deborah Morosini | -- | Executive Vice President and Chief of Clinical Affairs | 62 | 未披露 | 未持股 | 2020-08-21 |
| Christopher Pierce | 男 | Executive Vice President and Chief of Business Operations | 40 | 未披露 | 未持股 | 2020-08-21 |
董事简历
中英对照 | 中文 | 英文- Victor Sandor
-
Victor Sandor，2014年9月以来，他一直担任我们的首席医疗官。加入Array公司之前，他曾担任Incyte Corporation公司的高级副总裁，负责全球临床开发（始于2014年5月）。他最初于2010年2月加入Incyte公司，担任公司的副总裁，负责全球肿瘤药物开发。加入Incyte公司之前，他曾担任Biogen Idec公司的副总裁兼肿瘤首席医疗官（从2009年11月到2010年2月）。他曾担任 AstraZeneca公司的肿瘤产品开发职务，并不断被提拔（从2002年9月到2009年11月），在那里他曾担任关键职务，涉及Arimidex的辅助使用、Faslodex的开发、一些通过概念验证项目的早期发展阶段的开发。
Victor Sandor has served as a member of our board of directors since May 2020. From September 2014 to December 2019 Dr. Sandor served as the Chief Medical Officer at Array BioPharma Inc., a pharmaceutical company. From September 2014 to June 2019 he served as the Senior Vice President for Global Clinical Development at Incyte Corporation, a pharmaceutical company. From February 2010 to September 2014 Dr. Sandor served as the Vice President and Chief Medical Officer for oncology at Biogen Idec and, from October 2009 to February 2010 held positions of increasing responsibility in oncology product development at AstraZeneca. Dr. Sandor has served on the board of directors of ADC Therapeutics SA since April 2020 and Merus N.V. since June 2019. Dr. Sandor received a M.D.C.M. from McGill University in Montreal, Canada, and completed his Fellowship in Medical Oncology at the National Institutes of Health in Bethesda, Maryland. - Victor Sandor，2014年9月以来，他一直担任我们的首席医疗官。加入Array公司之前，他曾担任Incyte Corporation公司的高级副总裁，负责全球临床开发（始于2014年5月）。他最初于2010年2月加入Incyte公司，担任公司的副总裁，负责全球肿瘤药物开发。加入Incyte公司之前，他曾担任Biogen Idec公司的副总裁兼肿瘤首席医疗官（从2009年11月到2010年2月）。他曾担任 AstraZeneca公司的肿瘤产品开发职务，并不断被提拔（从2002年9月到2009年11月），在那里他曾担任关键职务，涉及Arimidex的辅助使用、Faslodex的开发、一些通过概念验证项目的早期发展阶段的开发。
- Victor Sandor has served as a member of our board of directors since May 2020. From September 2014 to December 2019 Dr. Sandor served as the Chief Medical Officer at Array BioPharma Inc., a pharmaceutical company. From September 2014 to June 2019 he served as the Senior Vice President for Global Clinical Development at Incyte Corporation, a pharmaceutical company. From February 2010 to September 2014 Dr. Sandor served as the Vice President and Chief Medical Officer for oncology at Biogen Idec and, from October 2009 to February 2010 held positions of increasing responsibility in oncology product development at AstraZeneca. Dr. Sandor has served on the board of directors of ADC Therapeutics SA since April 2020 and Merus N.V. since June 2019. Dr. Sandor received a M.D.C.M. from McGill University in Montreal, Canada, and completed his Fellowship in Medical Oncology at the National Institutes of Health in Bethesda, Maryland.
- Paul A. Friedman
-
Paul A. Friedman，自2016年7月起，Friedman博士担任Madrigal制药董事会主席和首席执行官。Friedman博士从2001年11月起担任 Incyte Corporation的CEO和董事，直到2014年1月退休。他曾担任杜邦默克制药公司研发总裁，同时担任杜邦制药研究实验室总裁，杜邦制药研究实验室是杜邦公司全资子公司。他还曾在杜邦制药研究实验室、默克研究实验室和默克夏普多姆公司担任执行和研发职位。弗里德曼博士在默克和杜邦任职之前，曾是哈佛医学院医学和药理学副教授。弗里德曼博士是美国内科委员会的外交官，也是美国临床调查学会的成员。他曾担任Cerulean Pharma Inc.和Verastem，Inc.的董事会成员。弗里德曼博士从普林斯顿大学获得生物学学士学位，哈佛医学院博士学位。
Paul A. Friedman,has served as our Chairman and Chief Executive Officer since July 22 2016. Dr. Friedman also currently serves on the Board of Prelude Therapeutics, a publicly-held biopharmaceutical company, where he serves as non-executive Chairman. Dr. Friedman served as the Chief Executive Officer of Incyte from November 2001 until his retirement in January 2014 and served on the Incyte Board of Directors from November 2001 until his retirement form that Board in May of 2021. Dr. Friedman served from 1994 to 1998 as President of Research & Development for the DuPont-Merck Pharmaceutical Company and from 1998 to 2001 as President of DuPont Pharmaceuticals Research Laboratories, a wholly-owned subsidiary of the DuPont Company. From 1991 to 1994 he served as Senior Vice President at Merck Research Laboratories. Prior to his tenures at Merck and DuPont, Dr. Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. Dr. Friedman is a diplomat of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. He also previously served on the board of directors of the following publicly-held pharmaceutical companies in the last five years: Alexion Pharmaceuticals through its proposed acquisition by AstraZeneca, subject to stockholder approval on May 11 2021; Cerulean Pharma Inc. (now Daré Bioscience, Inc.) (through January of 2017); and Verastem, Inc. (through April of 2017). Dr. Friedman received his A.B. in Biology from Princeton University and his M.D. from Harvard Medical School. Dr. Friedman and Dr. Taub, our Chief Medical Officer, President, Research & Development, and a director, are married. - Paul A. Friedman，自2016年7月起，Friedman博士担任Madrigal制药董事会主席和首席执行官。Friedman博士从2001年11月起担任 Incyte Corporation的CEO和董事，直到2014年1月退休。他曾担任杜邦默克制药公司研发总裁，同时担任杜邦制药研究实验室总裁，杜邦制药研究实验室是杜邦公司全资子公司。他还曾在杜邦制药研究实验室、默克研究实验室和默克夏普多姆公司担任执行和研发职位。弗里德曼博士在默克和杜邦任职之前，曾是哈佛医学院医学和药理学副教授。弗里德曼博士是美国内科委员会的外交官，也是美国临床调查学会的成员。他曾担任Cerulean Pharma Inc.和Verastem，Inc.的董事会成员。弗里德曼博士从普林斯顿大学获得生物学学士学位，哈佛医学院博士学位。
- Paul A. Friedman,has served as our Chairman and Chief Executive Officer since July 22 2016. Dr. Friedman also currently serves on the Board of Prelude Therapeutics, a publicly-held biopharmaceutical company, where he serves as non-executive Chairman. Dr. Friedman served as the Chief Executive Officer of Incyte from November 2001 until his retirement in January 2014 and served on the Incyte Board of Directors from November 2001 until his retirement form that Board in May of 2021. Dr. Friedman served from 1994 to 1998 as President of Research & Development for the DuPont-Merck Pharmaceutical Company and from 1998 to 2001 as President of DuPont Pharmaceuticals Research Laboratories, a wholly-owned subsidiary of the DuPont Company. From 1991 to 1994 he served as Senior Vice President at Merck Research Laboratories. Prior to his tenures at Merck and DuPont, Dr. Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. Dr. Friedman is a diplomat of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. He also previously served on the board of directors of the following publicly-held pharmaceutical companies in the last five years: Alexion Pharmaceuticals through its proposed acquisition by AstraZeneca, subject to stockholder approval on May 11 2021; Cerulean Pharma Inc. (now Daré Bioscience, Inc.) (through January of 2017); and Verastem, Inc. (through April of 2017). Dr. Friedman received his A.B. in Biology from Princeton University and his M.D. from Harvard Medical School. Dr. Friedman and Dr. Taub, our Chief Medical Officer, President, Research & Development, and a director, are married.
- Kelvin Neu
-
Kelvin Neu是贝克兄弟公司的合伙人。Advisors LP，注册投资顾问。Neu博士自2020年3月起担任生物技术公司ZymeworksInc.的董事会成员，自2019年7月起担任生物制药公司IGMBiosciences，Inc.的董事会成员，也是IGM&8217；的研究和临床开发委员会成员。Neu博士此前曾在Idera Pharmaceuticals、Aquinox Pharmaceuticals和XOMA Corporation董事会任职。Neu博士在普林斯顿大学（Princeton University）以优异成绩获得A.B.Summa，在那里他因首次在分子生物系毕业而获得Khoury奖。在进入普林斯顿大学之前，Neu博士在他的祖国新加坡的军队中服役了两年半。Neu博士在哈佛医学院（Harvard Medical School-MIT Health Sciences and Technology Program）获得医学博士学位，并在斯坦福大学（Stanford University）的免疫学博士课程中花了三年时间，担任霍华德·休斯医学研究所研究员。
Kelvin Neu has served as a member of Zymeworks Bc Inc. Board of Directors since March 2020. Dr. Neu was a Partner at Baker Bros. Advisors LP, a registered investment adviser, from April 2004 until January 2021. Dr. Neu previously served on the board of directors of IGM Biosciences, Prelude Therapeutics, Idera Pharmaceuticals, Aquinox Pharmaceuticals and XOMA Corporation. Dr. Neu holds an M.D. from the Harvard Medical School-MIT Health Sciences and Technology program, and spent three years in the Immunology Ph.D. program at Stanford University as a Howard Hughes Medical Institute Fellow. Dr. Neu holds an A.B. (summa cum laude) from Princeton University, where he was awarded the Khoury Prize for graduating first in his department of Molecular Biology. Prior to attending Princeton, Dr. Neu served for two and a half years in the military of his native Singapore. Dr. Neu is a resident of Singapore. - Kelvin Neu是贝克兄弟公司的合伙人。Advisors LP，注册投资顾问。Neu博士自2020年3月起担任生物技术公司ZymeworksInc.的董事会成员，自2019年7月起担任生物制药公司IGMBiosciences，Inc.的董事会成员，也是IGM&8217；的研究和临床开发委员会成员。Neu博士此前曾在Idera Pharmaceuticals、Aquinox Pharmaceuticals和XOMA Corporation董事会任职。Neu博士在普林斯顿大学（Princeton University）以优异成绩获得A.B.Summa，在那里他因首次在分子生物系毕业而获得Khoury奖。在进入普林斯顿大学之前，Neu博士在他的祖国新加坡的军队中服役了两年半。Neu博士在哈佛医学院（Harvard Medical School-MIT Health Sciences and Technology Program）获得医学博士学位，并在斯坦福大学（Stanford University）的免疫学博士课程中花了三年时间，担任霍华德·休斯医学研究所研究员。
- Kelvin Neu has served as a member of Zymeworks Bc Inc. Board of Directors since March 2020. Dr. Neu was a Partner at Baker Bros. Advisors LP, a registered investment adviser, from April 2004 until January 2021. Dr. Neu previously served on the board of directors of IGM Biosciences, Prelude Therapeutics, Idera Pharmaceuticals, Aquinox Pharmaceuticals and XOMA Corporation. Dr. Neu holds an M.D. from the Harvard Medical School-MIT Health Sciences and Technology program, and spent three years in the Immunology Ph.D. program at Stanford University as a Howard Hughes Medical Institute Fellow. Dr. Neu holds an A.B. (summa cum laude) from Princeton University, where he was awarded the Khoury Prize for graduating first in his department of Molecular Biology. Prior to attending Princeton, Dr. Neu served for two and a half years in the military of his native Singapore. Dr. Neu is a resident of Singapore.
- Kris Vaddi
-
Kris Vaddi自2016年2月起担任我们的首席执行官兼董事会成员。2014年6月至2016年6月，Vaddi博士还担任临床阶段生物技术公司Orsenix，LLC的首席执行官。Vaddi博士曾在因塞特医疗公司担任多个职位，最近的职位是2015年6月至2016年6月担任高级顾问，2010年3月至2015年6月担任集团Vice President。Vaddi博士在印度Acharya N.G.Ranga农业大学（Acharya N.G.Ranga Agricultural University）获得兽医学学士学位，在佛罗里达大学（University of Florida）获得药理学与毒理学博士学位。
Kris Vaddi has served as our Chief Executive Officer and a member of our board of directors since February 2016. From June 2014 to June 2016 Dr. Vaddi also served as Chief Executive Officer of Orsenix, LLC, a clinical stage biotechnology company. Dr. Vaddi previously held several roles at Incyte Corporation, most recently as Senior Advisor from June 2015 to June 2016 and Group Vice President from March 2010 to June 2015. Dr. Vaddi received a BVSc in Veterinary Medicine from Acharya N.G. Ranga Agricultural University in India and a Ph.D. in Pharmacology and Toxicology from the University of Florida. - Kris Vaddi自2016年2月起担任我们的首席执行官兼董事会成员。2014年6月至2016年6月，Vaddi博士还担任临床阶段生物技术公司Orsenix，LLC的首席执行官。Vaddi博士曾在因塞特医疗公司担任多个职位，最近的职位是2015年6月至2016年6月担任高级顾问，2010年3月至2015年6月担任集团Vice President。Vaddi博士在印度Acharya N.G.Ranga农业大学（Acharya N.G.Ranga Agricultural University）获得兽医学学士学位，在佛罗里达大学（University of Florida）获得药理学与毒理学博士学位。
- Kris Vaddi has served as our Chief Executive Officer and a member of our board of directors since February 2016. From June 2014 to June 2016 Dr. Vaddi also served as Chief Executive Officer of Orsenix, LLC, a clinical stage biotechnology company. Dr. Vaddi previously held several roles at Incyte Corporation, most recently as Senior Advisor from June 2015 to June 2016 and Group Vice President from March 2010 to June 2015. Dr. Vaddi received a BVSc in Veterinary Medicine from Acharya N.G. Ranga Agricultural University in India and a Ph.D. in Pharmacology and Toxicology from the University of Florida.
- David Bonita
-
David Bonita，2012年10月以来担任我们的董事之一。他是私人股本团队OrbiMed Advisors LLC投资公司的主要负责人，2004年6月以来担任该职位。从1998年到1999年，他是医疗保健投资银行集团摩根士丹利（Morgan Stanley）的投资公司的金融分析师从1997年到1998年，他在医疗保健投资银行瑞士银行（UBS AG担任金融分析师。
David Bonita has served as a member of our board of directors since March 2016. Dr. Bonita is a member of OrbiMed Advisors LLC, an investment firm. Dr. Bonita currently serves on the boards of directors of Acutus Medical Inc. Nasdaq: AFIB, IMARA Inc. (Nasdaq: IMRA), Prelude Therapeutics, Inc. (Nasdaq: PRLD), Repare Therapeutics Inc. (Nasdaq: RPTX), and Tricida, Inc. (Nasdaq: TCDA), as well as several private companies. Dr. Bonita also previously served on the boards of directors of Clementia Pharmaceuticals Inc., Loxo Oncology, Inc., SI-BONE, Inc., and ViewRay Inc. Prior to OrbiMed, Dr. Bonita worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He has published scientific articles in peer-reviewed journals based on signal transduction research performed at Harvard Medical School. He received his B.A. in biology from Harvard University and his joint M.D./M.B.A. from Columbia University. - David Bonita，2012年10月以来担任我们的董事之一。他是私人股本团队OrbiMed Advisors LLC投资公司的主要负责人，2004年6月以来担任该职位。从1998年到1999年，他是医疗保健投资银行集团摩根士丹利（Morgan Stanley）的投资公司的金融分析师从1997年到1998年，他在医疗保健投资银行瑞士银行（UBS AG担任金融分析师。
- David Bonita has served as a member of our board of directors since March 2016. Dr. Bonita is a member of OrbiMed Advisors LLC, an investment firm. Dr. Bonita currently serves on the boards of directors of Acutus Medical Inc. Nasdaq: AFIB, IMARA Inc. (Nasdaq: IMRA), Prelude Therapeutics, Inc. (Nasdaq: PRLD), Repare Therapeutics Inc. (Nasdaq: RPTX), and Tricida, Inc. (Nasdaq: TCDA), as well as several private companies. Dr. Bonita also previously served on the boards of directors of Clementia Pharmaceuticals Inc., Loxo Oncology, Inc., SI-BONE, Inc., and ViewRay Inc. Prior to OrbiMed, Dr. Bonita worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He has published scientific articles in peer-reviewed journals based on signal transduction research performed at Harvard Medical School. He received his B.A. in biology from Harvard University and his joint M.D./M.B.A. from Columbia University.
- Mardi C. Dier
-
Mardi C. Dier，2006年8月起，担任本公司的执行副总裁、首席财务官。2003年6月至2006年7月，她在生物制药公司Chiron Corporation担任投资者关系副总裁。1994-2001，她担任证券公司Prudential Securities的投资银行部总监。之前，1986-1990，她是会计师事务所KPMG LLP审计部门的监管高级会计师。她获得了Stanford University的生物学士学位、Anderson Graduate School of Management at the University of California, Los Angeles。的工商管理硕士学位。
Mardi C. Dier has served as a member of Prelude Therapeutics Inc board of directors since August 2020. Ms. Dier most recently served as Executive Vice President and Chief Financial Officer, and also as Chief Business Officer, of Portola Pharmaceuticals, Inc., a biopharmaceutical company, from November 2013 and October 2018 respectively, until its acquisition by Alexion Pharmaceuticals in July 2020 and as a Senior Vice President and Chief Financial Officer from August 2006 to November 2013. From 2003 to 2006 Ms. Dier served as Vice President of Investor Relations at Chiron Corporation, a biopharmaceutical company. From 1994 to 2001 Ms. Dier served as a Director, Investment Banking at Prudential Securities, Inc., a securities firm. Ms. Dier previously served as a supervising senior accountant at the audit department of KPMG Peat Marwick, an accounting firm, from 1986 to 1990. Ms. Dier currently serves as a director, and member of the audit committee, of Adamas Pharmaceuticals, Inc., a biopharmaceutical company, and as a director of ORIC Pharmaceuticals, Inc. Ms. Dier received a B.S. in Biology from Stanford University and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles. - Mardi C. Dier，2006年8月起，担任本公司的执行副总裁、首席财务官。2003年6月至2006年7月，她在生物制药公司Chiron Corporation担任投资者关系副总裁。1994-2001，她担任证券公司Prudential Securities的投资银行部总监。之前，1986-1990，她是会计师事务所KPMG LLP审计部门的监管高级会计师。她获得了Stanford University的生物学士学位、Anderson Graduate School of Management at the University of California, Los Angeles。的工商管理硕士学位。
- Mardi C. Dier has served as a member of Prelude Therapeutics Inc board of directors since August 2020. Ms. Dier most recently served as Executive Vice President and Chief Financial Officer, and also as Chief Business Officer, of Portola Pharmaceuticals, Inc., a biopharmaceutical company, from November 2013 and October 2018 respectively, until its acquisition by Alexion Pharmaceuticals in July 2020 and as a Senior Vice President and Chief Financial Officer from August 2006 to November 2013. From 2003 to 2006 Ms. Dier served as Vice President of Investor Relations at Chiron Corporation, a biopharmaceutical company. From 1994 to 2001 Ms. Dier served as a Director, Investment Banking at Prudential Securities, Inc., a securities firm. Ms. Dier previously served as a supervising senior accountant at the audit department of KPMG Peat Marwick, an accounting firm, from 1986 to 1990. Ms. Dier currently serves as a director, and member of the audit committee, of Adamas Pharmaceuticals, Inc., a biopharmaceutical company, and as a director of ORIC Pharmaceuticals, Inc. Ms. Dier received a B.S. in Biology from Stanford University and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles.
高管简历
中英对照 | 中文 | 英文- Brian Piper
Brian Piper，他曾一直担任我们的首席财务官（2016年2月以来），此前曾担任我们的财务和投资者关系副总裁（2014年4月加入我们公司以来）。此前，他曾任职Shire Pharmaceuticals公司（一个全球性的专业制药公司）13年，也曾担任多种财务和投资者关系职务，并不断被提拔，包括担任高级商业开发主管（2010年1月至2014年3月），也曾从事在爱尔兰都柏林建立Shire公司的地理扩张策略。加入Shire公司之前，他曾任职Celera Genomics公司、Otsuka Pharmaceuticals公司。他持有the University of Notre Dame的工商管理学士学位，以及the Robert H. Smith School of Business at the University of Maryland的工商管理硕士学位。
Brian Piper has served as our Chief Financial Officer since July 2019. Mr. Piper previously served as Chief Financial Officer and Corporate Secretary at Aevi Genomic Medicine, Inc., a biopharmaceutical company later acquired by Cerecor, Inc., from February 2016 until May 2019. Prior to his time at Aevi, Mr. Piper served as Vice President Finance & Investor Relations at Medgenics, Inc., a biotechnology company from April 2014 until January 2016. Prior to that, Mr. Piper served in several roles at Shire Pharmaceuticals plc (later acquired by Takeda Pharmaceutical Company Limited), most recently in Business Development from January 2010 until March 2014. Mr. Piper received a B.B.A. in Finance from the University of Notre Dame and an M.B.A. from the Robert H. Smith School of Business at the University of Maryland.- Brian Piper，他曾一直担任我们的首席财务官（2016年2月以来），此前曾担任我们的财务和投资者关系副总裁（2014年4月加入我们公司以来）。此前，他曾任职Shire Pharmaceuticals公司（一个全球性的专业制药公司）13年，也曾担任多种财务和投资者关系职务，并不断被提拔，包括担任高级商业开发主管（2010年1月至2014年3月），也曾从事在爱尔兰都柏林建立Shire公司的地理扩张策略。加入Shire公司之前，他曾任职Celera Genomics公司、Otsuka Pharmaceuticals公司。他持有the University of Notre Dame的工商管理学士学位，以及the Robert H. Smith School of Business at the University of Maryland的工商管理硕士学位。
- Brian Piper has served as our Chief Financial Officer since July 2019. Mr. Piper previously served as Chief Financial Officer and Corporate Secretary at Aevi Genomic Medicine, Inc., a biopharmaceutical company later acquired by Cerecor, Inc., from February 2016 until May 2019. Prior to his time at Aevi, Mr. Piper served as Vice President Finance & Investor Relations at Medgenics, Inc., a biotechnology company from April 2014 until January 2016. Prior to that, Mr. Piper served in several roles at Shire Pharmaceuticals plc (later acquired by Takeda Pharmaceutical Company Limited), most recently in Business Development from January 2010 until March 2014. Mr. Piper received a B.B.A. in Finance from the University of Notre Dame and an M.B.A. from the Robert H. Smith School of Business at the University of Maryland.
- Kris Vaddi
Kris Vaddi自2016年2月起担任我们的首席执行官兼董事会成员。2014年6月至2016年6月，Vaddi博士还担任临床阶段生物技术公司Orsenix，LLC的首席执行官。Vaddi博士曾在因塞特医疗公司担任多个职位，最近的职位是2015年6月至2016年6月担任高级顾问，2010年3月至2015年6月担任集团Vice President。Vaddi博士在印度Acharya N.G.Ranga农业大学（Acharya N.G.Ranga Agricultural University）获得兽医学学士学位，在佛罗里达大学（University of Florida）获得药理学与毒理学博士学位。
Kris Vaddi has served as our Chief Executive Officer and a member of our board of directors since February 2016. From June 2014 to June 2016 Dr. Vaddi also served as Chief Executive Officer of Orsenix, LLC, a clinical stage biotechnology company. Dr. Vaddi previously held several roles at Incyte Corporation, most recently as Senior Advisor from June 2015 to June 2016 and Group Vice President from March 2010 to June 2015. Dr. Vaddi received a BVSc in Veterinary Medicine from Acharya N.G. Ranga Agricultural University in India and a Ph.D. in Pharmacology and Toxicology from the University of Florida.- Kris Vaddi自2016年2月起担任我们的首席执行官兼董事会成员。2014年6月至2016年6月，Vaddi博士还担任临床阶段生物技术公司Orsenix，LLC的首席执行官。Vaddi博士曾在因塞特医疗公司担任多个职位，最近的职位是2015年6月至2016年6月担任高级顾问，2010年3月至2015年6月担任集团Vice President。Vaddi博士在印度Acharya N.G.Ranga农业大学（Acharya N.G.Ranga Agricultural University）获得兽医学学士学位，在佛罗里达大学（University of Florida）获得药理学与毒理学博士学位。
- Kris Vaddi has served as our Chief Executive Officer and a member of our board of directors since February 2016. From June 2014 to June 2016 Dr. Vaddi also served as Chief Executive Officer of Orsenix, LLC, a clinical stage biotechnology company. Dr. Vaddi previously held several roles at Incyte Corporation, most recently as Senior Advisor from June 2015 to June 2016 and Group Vice President from March 2010 to June 2015. Dr. Vaddi received a BVSc in Veterinary Medicine from Acharya N.G. Ranga Agricultural University in India and a Ph.D. in Pharmacology and Toxicology from the University of Florida.
- David Mauro
David Mauro自2019年5月起担任我们的首席医疗官。Mauro博士此前曾于2016年2月至2019年4月担任生物制药公司Checkmate Pharmaceuticals Inc.的首席医疗官。在此之前，毛罗博士于2014年10月至2016年2月担任Advaxis，Inc.首席医疗官。他曾担任Merck公司的执行董事（从2007年到2014年），此前曾担任Bristol Myers Squibb公司的董事。Mauro博士在康奈尔大学（Cornell University）获得生物化学学士学位，并在坦普尔大学医学院（Temple University School of Medicine）获得医学博士学位和博士学位。
David Mauro has served as our Chief Medical Officer since May 2019. Dr. Mauro previously served as Chief Medical Officer at Checkmate Pharmaceuticals Inc., a biopharmaceutical company, from February 2016 until April 2019. Prior to that, Dr. Mauro served as Chief Medical Officer at Advaxis, Inc. from October 2014 until February 2016. Dr. Mauro served as Executive Director at Merck from 2007-2014 and prior to that he was Director at Bristol Myers Squibb. Dr. Mauro received a B.S. in Biochemistry from Cornell University and an M.D. and Ph.D. from Temple University School of Medicine.- David Mauro自2019年5月起担任我们的首席医疗官。Mauro博士此前曾于2016年2月至2019年4月担任生物制药公司Checkmate Pharmaceuticals Inc.的首席医疗官。在此之前，毛罗博士于2014年10月至2016年2月担任Advaxis，Inc.首席医疗官。他曾担任Merck公司的执行董事（从2007年到2014年），此前曾担任Bristol Myers Squibb公司的董事。Mauro博士在康奈尔大学（Cornell University）获得生物化学学士学位，并在坦普尔大学医学院（Temple University School of Medicine）获得医学博士学位和博士学位。
- David Mauro has served as our Chief Medical Officer since May 2019. Dr. Mauro previously served as Chief Medical Officer at Checkmate Pharmaceuticals Inc., a biopharmaceutical company, from February 2016 until April 2019. Prior to that, Dr. Mauro served as Chief Medical Officer at Advaxis, Inc. from October 2014 until February 2016. Dr. Mauro served as Executive Director at Merck from 2007-2014 and prior to that he was Director at Bristol Myers Squibb. Dr. Mauro received a B.S. in Biochemistry from Cornell University and an M.D. and Ph.D. from Temple University School of Medicine.
- Peggy A. Scherle
Peggy A.Scherle自2018年4月起担任我们的首席科学官。Scherle博士此前曾在制药公司因塞特医疗公司担任多个职位，最近的职位是从2017年3月至2018年3月担任集团Vice President，发现生物学和临床前药理学。2014年至2017年，她在Incyte担任临床前药理学Vice President，2011年至2014年担任体外生物学执行董事。在她职业生涯的早期，Scherle博士在杜邦制药公司（DuPont Pharmaceuticals）和百时美施贵宝公司（Bristol-Myers Squibb）担任科学研究职位。Scherle博士在密歇根州立大学（Michigan State University）获得生物化学B.S.学位，在宾夕法尼亚大学（University of Pennsylvania）获得免疫学博士学位。她在美国国立卫生研究院（National Institutes of Health）完成博士后培训。
Peggy A. Scherle has served as our Chief Scientific Officer since April 2018. Dr. Scherle previously held several roles at Incyte Corporation, a pharmaceutical company, most recently as Group Vice President, Discovery Biology and Preclinical Pharmacology from March 2017 until March 2018. Her prior roles at Incyte included Vice President, Preclinical Pharmacology from 2014 until 2017 and as Executive Director, In Vitro Biology from 2011 until 2014. Earlier in her career, Dr. Scherle held scientific research positions with DuPont Pharmaceuticals and Bristol-Myers Squibb. Dr. Scherle received a B.S. degree in Biochemistry from Michigan State University and a Ph.D. in Immunology from the University of Pennsylvania. She completed her postdoctoral training at the National Institutes of Health.- Peggy A.Scherle自2018年4月起担任我们的首席科学官。Scherle博士此前曾在制药公司因塞特医疗公司担任多个职位，最近的职位是从2017年3月至2018年3月担任集团Vice President，发现生物学和临床前药理学。2014年至2017年，她在Incyte担任临床前药理学Vice President，2011年至2014年担任体外生物学执行董事。在她职业生涯的早期，Scherle博士在杜邦制药公司（DuPont Pharmaceuticals）和百时美施贵宝公司（Bristol-Myers Squibb）担任科学研究职位。Scherle博士在密歇根州立大学（Michigan State University）获得生物化学B.S.学位，在宾夕法尼亚大学（University of Pennsylvania）获得免疫学博士学位。她在美国国立卫生研究院（National Institutes of Health）完成博士后培训。
- Peggy A. Scherle has served as our Chief Scientific Officer since April 2018. Dr. Scherle previously held several roles at Incyte Corporation, a pharmaceutical company, most recently as Group Vice President, Discovery Biology and Preclinical Pharmacology from March 2017 until March 2018. Her prior roles at Incyte included Vice President, Preclinical Pharmacology from 2014 until 2017 and as Executive Director, In Vitro Biology from 2011 until 2014. Earlier in her career, Dr. Scherle held scientific research positions with DuPont Pharmaceuticals and Bristol-Myers Squibb. Dr. Scherle received a B.S. degree in Biochemistry from Michigan State University and a Ph.D. in Immunology from the University of Pennsylvania. She completed her postdoctoral training at the National Institutes of Health.
- Andrew P. Combs
Andrew P.Combs自2019年4月起担任我们的执行Vice President兼化学主管。2003年1月至2019年2月，康布斯博士曾在制药公司因塞特医疗公司担任多个职位，最近担任发现化学Vice President，领导药物化学，分析化学，使能技术，计算设计和信息学团队。他之前在Incyte的职位包括从2003年到2006年担任高级总监，从2006年到2015年担任执行总监，从2015年到2019年担任Vice President。在职业生涯早期，Combs博士担任职责递增的职位，开始担任高级研究科学家，并晋升为杜邦-默克公司、杜邦制药公司和百时美施贵宝公司的药物化学董事。Combs博士在威斯康星大学麦迪逊分校（University of Wisconsin-Madison）获得化学与分子生物学B.S.学位，在加州大学洛杉矶分校（University of California，Los Angeles）获得有机化学博士学位，并在哈佛大学（Harvard University）完成了作为霍华德休斯医学院博士后的培训。
Andrew P. Combs has served as our Executive Vice President and Head of Chemistry since April 2019. Dr. Combs previously held several roles at Incyte Corporation, a pharmaceutical company, most recently as Vice President of Discovery Chemistry where he led teams in medicinal chemistry, analytical chemistry, enabling technologies, computational design and informatics from January 2003 until February 2019. His prior roles at Incyte included as Senior Director from 2003 until 2006 and as Executive Director from 2006 until 2015 and Vice President from 2015 until 2019. Earlier in his career, Dr. Combs held positions of increasing responsibility, starting as a Senior Research Scientist and advancing to a Director of medicinal chemistry at DuPont-Merck, DuPont Pharmaceuticals and Bristol-Myers Squibb. Dr. Combs received B.S. degrees in Chemistry and Molecular Biology from the University of Wisconsin-Madison, a Ph.D. in Organic Chemistry from the University of California, Los Angeles, and completed his training as a Howard Hughes Medical Institute post-doctoral fellow at Harvard University.- Andrew P.Combs自2019年4月起担任我们的执行Vice President兼化学主管。2003年1月至2019年2月，康布斯博士曾在制药公司因塞特医疗公司担任多个职位，最近担任发现化学Vice President，领导药物化学，分析化学，使能技术，计算设计和信息学团队。他之前在Incyte的职位包括从2003年到2006年担任高级总监，从2006年到2015年担任执行总监，从2015年到2019年担任Vice President。在职业生涯早期，Combs博士担任职责递增的职位，开始担任高级研究科学家，并晋升为杜邦-默克公司、杜邦制药公司和百时美施贵宝公司的药物化学董事。Combs博士在威斯康星大学麦迪逊分校（University of Wisconsin-Madison）获得化学与分子生物学B.S.学位，在加州大学洛杉矶分校（University of California，Los Angeles）获得有机化学博士学位，并在哈佛大学（Harvard University）完成了作为霍华德休斯医学院博士后的培训。
- Andrew P. Combs has served as our Executive Vice President and Head of Chemistry since April 2019. Dr. Combs previously held several roles at Incyte Corporation, a pharmaceutical company, most recently as Vice President of Discovery Chemistry where he led teams in medicinal chemistry, analytical chemistry, enabling technologies, computational design and informatics from January 2003 until February 2019. His prior roles at Incyte included as Senior Director from 2003 until 2006 and as Executive Director from 2006 until 2015 and Vice President from 2015 until 2019. Earlier in his career, Dr. Combs held positions of increasing responsibility, starting as a Senior Research Scientist and advancing to a Director of medicinal chemistry at DuPont-Merck, DuPont Pharmaceuticals and Bristol-Myers Squibb. Dr. Combs received B.S. degrees in Chemistry and Molecular Biology from the University of Wisconsin-Madison, a Ph.D. in Organic Chemistry from the University of California, Los Angeles, and completed his training as a Howard Hughes Medical Institute post-doctoral fellow at Harvard University.
- Deborah Morosini
Deborah Morosini自2020年7月起担任我们的执行Vice President兼临床事务主管，并于2019年7月至2020年7月担任我们和其他多家肿瘤公司的独立顾问。Morosini博士曾于2016年4月至2019年4月担任生物制药公司LoxoOncology，Inc.临床事务和患者参与Vice President。Morosini博士于2013年8月至2016年4月在分子信息公司FoundationMedicine，Inc.担任临床事务和患者参与Vice President。Morosini博士在Mount Holyoke College获得英语学士学位，在New York University&8217；s Graduate School of Social Work获得M.S.W.学位，在Boston University School of Medicine获得医学博士学位。
Deborah Morosini has served as our Executive Vice President and Chief of Clinical Affairs since July 2020 and was an independent consultant to us and various other oncology companies from July 2019 to July 2020. Dr. Morosini previously served as Vice President of Clinical Affairs and Patient Engagement at Loxo Oncology, Inc., a biopharmaceutical company, from April 2016 to April 2019. Dr. Morosini served as Vice President of Clinical Affairs and Patient Engagement from August 2013 to April 2016 at Foundation Medicine, Inc., a molecular information company. Dr. Morosini received a B.A. degree in English from Mount Holyoke College, an M.S.W. degree from New York University’s Graduate School of Social Work and an M.D. from Boston University School of Medicine.- Deborah Morosini自2020年7月起担任我们的执行Vice President兼临床事务主管，并于2019年7月至2020年7月担任我们和其他多家肿瘤公司的独立顾问。Morosini博士曾于2016年4月至2019年4月担任生物制药公司LoxoOncology，Inc.临床事务和患者参与Vice President。Morosini博士于2013年8月至2016年4月在分子信息公司FoundationMedicine，Inc.担任临床事务和患者参与Vice President。Morosini博士在Mount Holyoke College获得英语学士学位，在New York University&8217；s Graduate School of Social Work获得M.S.W.学位，在Boston University School of Medicine获得医学博士学位。
- Deborah Morosini has served as our Executive Vice President and Chief of Clinical Affairs since July 2020 and was an independent consultant to us and various other oncology companies from July 2019 to July 2020. Dr. Morosini previously served as Vice President of Clinical Affairs and Patient Engagement at Loxo Oncology, Inc., a biopharmaceutical company, from April 2016 to April 2019. Dr. Morosini served as Vice President of Clinical Affairs and Patient Engagement from August 2013 to April 2016 at Foundation Medicine, Inc., a molecular information company. Dr. Morosini received a B.A. degree in English from Mount Holyoke College, an M.S.W. degree from New York University’s Graduate School of Social Work and an M.D. from Boston University School of Medicine.
- Christopher Pierce
Christopher Pierce自2020年7月起担任我们的执行Vice President兼业务运营主管。Pierce先生此前于2019年8月至2020年7月担任生命科学咨询公司Scout Advisers，LLC的负责人兼创始人。在此之前，皮尔斯先生于2018年1月至2019年5月担任Vice President兼商业主管，并于2017年4月至2017年12月担任生物制药公司LoxoOncology，Inc.的商业执行董事。Pierce先生曾在生物制药公司辉瑞公司担任多个职位，包括2016年7月至2017年3月担任血液系统恶性肿瘤投资组合高级总监/全球商业主管，2015年3月至2016年7月担任美国市场营销投资组合主管。Pierce先生在哈佛学院（Harvard College）获得生化科学A.B.学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Christopher Pierce has served as our Executive Vice President and Chief of Business Operations since July 2020. Mr. Pierce previously served as Principal and Founder of Scout Advisers, LLC, a life sciences consultancy, from August 2019 to July 2020. Prior to that, Mr. Pierce served as Vice President, Head of Commercial from January 2018 to May 2019 and as Executive Director, Commercial from April 2017 to December 2017 at Loxo Oncology, Inc., a biopharmaceutical company. Mr. Pierce held several roles at Pfizer Inc., a biopharmaceutical company, including as Senior Director/Global Commercial Lead, Hematologic Malignancies Portfolio from July 2016 to March 2017 and as Portfolio Lead, US Marketing from March 2015 to July 2016. Mr. Pierce received an A.B. degree in Biochemical Sciences from Harvard College, and an M.B.A. from the Harvard Business School.- Christopher Pierce自2020年7月起担任我们的执行Vice President兼业务运营主管。Pierce先生此前于2019年8月至2020年7月担任生命科学咨询公司Scout Advisers，LLC的负责人兼创始人。在此之前，皮尔斯先生于2018年1月至2019年5月担任Vice President兼商业主管，并于2017年4月至2017年12月担任生物制药公司LoxoOncology，Inc.的商业执行董事。Pierce先生曾在生物制药公司辉瑞公司担任多个职位，包括2016年7月至2017年3月担任血液系统恶性肿瘤投资组合高级总监/全球商业主管，2015年3月至2016年7月担任美国市场营销投资组合主管。Pierce先生在哈佛学院（Harvard College）获得生化科学A.B.学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Christopher Pierce has served as our Executive Vice President and Chief of Business Operations since July 2020. Mr. Pierce previously served as Principal and Founder of Scout Advisers, LLC, a life sciences consultancy, from August 2019 to July 2020. Prior to that, Mr. Pierce served as Vice President, Head of Commercial from January 2018 to May 2019 and as Executive Director, Commercial from April 2017 to December 2017 at Loxo Oncology, Inc., a biopharmaceutical company. Mr. Pierce held several roles at Pfizer Inc., a biopharmaceutical company, including as Senior Director/Global Commercial Lead, Hematologic Malignancies Portfolio from July 2016 to March 2017 and as Portfolio Lead, US Marketing from March 2015 to July 2016. Mr. Pierce received an A.B. degree in Biochemical Sciences from Harvard College, and an M.B.A. from the Harvard Business School.